Rhythm Pharmaceuticals (RYTM) Change in Accured Expenses (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Change in Accured Expenses data on file, last reported at -$5.6 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$5.6 million, down 54.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.9 million (up 1.9% YoY), and the FY2025 annual result was $21.9 million, changed 0.12% from the prior year.
• Change in Accured Expenses slipped to -$5.6 million in Q1 2026 per RYTM's latest filing, from $1.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $15.7 million in Q4 2022 and troughed at -$12.6 million in Q3 2022.
• A 5-year average of $3.2 million and a median of $1.3 million in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses slumped 309.83% in 2022, then soared 9849.06% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $15.7 million in 2022, then tumbled by 69.08% to $4.9 million in 2023, then surged by 212.45% to $15.2 million in 2024, then slumped by 91.73% to $1.3 million in 2025, then slumped by 547.65% to -$5.6 million in 2026.
• Business Quant data shows RYTM's Change in Accured Expenses at -$5.6 million in Q1 2026, $1.3 million in Q4 2025, and $11.0 million in Q3 2025.